-
Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxel
-
Ongoing complete response has been maintained since the patient started treatment with efti monotherapy
-
Efti + paclitaxel combination continues to be well tolerated with a favourable safety profile
-
First-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level up to 96 hours after administration
-
Data from randomized Phase II portion of study expected in CY2024
SYDNEY, AUSTRALIA – May 15, 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces encouraging efficacy, safety, and pharmacodynamic data from the safety lead-in of the AIPAC-003 Phase II/III trial presented at the European Society for Medical Oncology (ESMO) Breast Cancer 2024 Congress. This lead-in represents the first ever 90mg dosing of eftilagimod alpha (“efti”), a soluble LAG-3 protein and MHC Class II agonist, given in combination with weekly paclitaxel.
For more information, download the attached PDF.
Download this document
